New Launch27 Feb 2026, 03:42 pm
Abbott India partners with Novo Nordisk India to launch Extensior, broadening access to Semaglutide for advanced diabetes management
AI Summary
Abbott India has partnered with Novo Nordisk India to commercialize Extensior, a second brand of Ozempic, in India. This partnership aims to expand access to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves. Extensior offers powerful HbAlc reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. The active ingredient in Extensior, semaglutide, is 94% homogenous to the naturally-occurring GLP-1 in the human body and was added to the WHO’s essential medicines list in 2025.
Key Highlights
- Abbott India has partnered with Novo Nordisk India to launch Extensior, a second brand of Ozempic, in India.
- This partnership aims to expand access to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves.
- Extensior offers powerful HbAlc reduction, weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes.
- Semaglutide, the active ingredient in Extensior, is 94% homogenous to the naturally-occurring GLP-1 in the human body and was added to the WHO’s essential medicines list in 2025.
- This launch is a meaningful step forward in expanding access to a solution that addresses holistic management of diabetes.